Review

chrdl1 genes (OriGene)

OriGene is a verified supplier

OriGene manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

OriGene chrdl1 genes

Decreased expression of <t>CHRDL1</t> in pancreatic cancer. (A) Data-based prediction of CHRDL1 expression in pancreatic cancer cells, two-tailed Student’s t-test. (B) Association between CHRDL1 and disease-free survival (DFS). (C-E) The efficiency of CHRDL1 overexpression in the pancreatic cancer cell lines PANC-1 and SW1990 was verified using quantitative real-time PCR (RT-qPCR) and Western blot analysis (n = 6, * P < 0.05 vs. hTERT-HPNE, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group). (F, G) IHC analysis of CHRDL1 in tumor and adjacent tissues (n = 6, * P < 0.05 vs. adjacent, two-tailed Student’s t-test).

Chrdl1 Genes, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chrdl1/CHRDL1+(NM_145234)+Human+Tagged+ORF+Clone/pmc12361159-45-3-5
Average 93 stars, based on 2 article reviews

chrdl1 genes - by Bioz Stars, 2026-09

93/100 stars

Images

1) Product Images from "Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway"

Article Title: Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway

Journal: Frontiers in Oncology

doi: 10.3389/fonc.2025.1633464

Decreased expression of CHRDL1 in pancreatic cancer. (A) Data-based prediction of CHRDL1 expression in pancreatic cancer cells, two-tailed Student’s t-test. (B) Association between CHRDL1 and disease-free survival (DFS). (C-E) The efficiency of CHRDL1 overexpression in the pancreatic cancer cell lines PANC-1 and SW1990 was verified using quantitative real-time PCR (RT-qPCR) and Western blot analysis (n = 6, * P < 0.05 vs. hTERT-HPNE, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group). (F, G) IHC analysis of CHRDL1 in tumor and adjacent tissues (n = 6, * P < 0.05 vs. adjacent, two-tailed Student’s t-test).

Figure Legend Snippet: Decreased expression of CHRDL1 in pancreatic cancer. (A) Data-based prediction of CHRDL1 expression in pancreatic cancer cells, two-tailed Student’s t-test. (B) Association between CHRDL1 and disease-free survival (DFS). (C-E) The efficiency of CHRDL1 overexpression in the pancreatic cancer cell lines PANC-1 and SW1990 was verified using quantitative real-time PCR (RT-qPCR) and Western blot analysis (n = 6, * P < 0.05 vs. hTERT-HPNE, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group). (F, G) IHC analysis of CHRDL1 in tumor and adjacent tissues (n = 6, * P < 0.05 vs. adjacent, two-tailed Student’s t-test).

Techniques Used: Expressing, Two Tailed Test, Over Expression, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Western Blot

Overexpression of CHRDL1 inhibits malignant biological behaviors of PANC-1 and SW1990 cells. (A, B) Representative images of wound healing at 0 and 24 h in CHRDL1 transduced PANC-1 cells, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (C, D) Migration and invasion assays of transfected PANC-1 cells, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). (E, F) Representative images of wound healing at 0 and 24 h in CHRDL1 transduced SW1990 cells, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (G, H) Migration and invasion assays of transfected SW1990 cells, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). n = 6 in each group, * P < 0.05 vs. control, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Figure Legend Snippet: Overexpression of CHRDL1 inhibits malignant biological behaviors of PANC-1 and SW1990 cells. (A, B) Representative images of wound healing at 0 and 24 h in CHRDL1 transduced PANC-1 cells, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (C, D) Migration and invasion assays of transfected PANC-1 cells, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). (E, F) Representative images of wound healing at 0 and 24 h in CHRDL1 transduced SW1990 cells, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (G, H) Migration and invasion assays of transfected SW1990 cells, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). n = 6 in each group, * P < 0.05 vs. control, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Techniques Used: Over Expression, Migration, Transfection, Control

Overexpression of CHRDL1 inhibits BMP4-Induced SMAD phosphorylation in pancreatic cancer cells. (A, B) p-SMAD 1/5/9, t-SMAD 1/5/9, RUNX2 and CHRDL1 protein levels in PANC-1 cells were detected using Western blots. The immunoblots were calculated by densitometric analysis using GAPDH as the internal reference. (C, D) p-SMAD 1/5/9, t-SMAD 1/5/9, RUNX2 and CHRDL1 protein levels in SW1990 cells were detected using Western blots. The immunoblots were calculated by densitometric analysis using GAPDH as the internal reference. n = 6 in each group, * P < 0.05 vs. OE-NC, # P < 0.05 rhBMP4+OE-NC, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Figure Legend Snippet: Overexpression of CHRDL1 inhibits BMP4-Induced SMAD phosphorylation in pancreatic cancer cells. (A, B) p-SMAD 1/5/9, t-SMAD 1/5/9, RUNX2 and CHRDL1 protein levels in PANC-1 cells were detected using Western blots. The immunoblots were calculated by densitometric analysis using GAPDH as the internal reference. (C, D) p-SMAD 1/5/9, t-SMAD 1/5/9, RUNX2 and CHRDL1 protein levels in SW1990 cells were detected using Western blots. The immunoblots were calculated by densitometric analysis using GAPDH as the internal reference. n = 6 in each group, * P < 0.05 vs. OE-NC, # P < 0.05 rhBMP4+OE-NC, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Techniques Used: Over Expression, Phospho-proteomics, Western Blot

CHRDL1 attenuates BMP4-induced malignant biological behaviors of pancreatic cancer cells. (A, B) Representative wound healing images of CHRDL1-transduced PANC-1 cells treated with rhBMP4 at 0 and 12 hours, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (C, D) Migration and invasion assays of transfected PANC-1 cells treated with rhBMP4, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). (E, F) Representative wound healing images of CHRDL1-transduced SW1990 cells treated with rhBMP4 at 0 and 12 hours, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (G, H) Migration and invasion assays of transfected SW1990 cells treated with rhBMP4, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm).n = 6 in each group, *P < 0.05 vs. OE-NC, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Figure Legend Snippet: CHRDL1 attenuates BMP4-induced malignant biological behaviors of pancreatic cancer cells. (A, B) Representative wound healing images of CHRDL1-transduced PANC-1 cells treated with rhBMP4 at 0 and 12 hours, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (C, D) Migration and invasion assays of transfected PANC-1 cells treated with rhBMP4, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). (E, F) Representative wound healing images of CHRDL1-transduced SW1990 cells treated with rhBMP4 at 0 and 12 hours, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (G, H) Migration and invasion assays of transfected SW1990 cells treated with rhBMP4, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm).n = 6 in each group, *P < 0.05 vs. OE-NC, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Techniques Used: Migration, Transfection

CHRDL1 inhibits pancreatic cancer metastasis in vivo. (A, B) Representative lung images of BALB/c nude mice at 9 weeks after tail vein injection with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). (C, D) Lung weights of BALB/c nude mice at 9 weeks after tail vein injection with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). (E-H) H&E-stained lung sections and corresponding quantitative analysis of tumor area/total lung area from mice injected with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). Scale bars, upper: 2 mm, lower: 100 μm. n = 6 in each group, * P < 0.05 vs. OE-NC, two-tailed Student’s t-test.

Figure Legend Snippet: CHRDL1 inhibits pancreatic cancer metastasis in vivo. (A, B) Representative lung images of BALB/c nude mice at 9 weeks after tail vein injection with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). (C, D) Lung weights of BALB/c nude mice at 9 weeks after tail vein injection with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). (E-H) H&E-stained lung sections and corresponding quantitative analysis of tumor area/total lung area from mice injected with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). Scale bars, upper: 2 mm, lower: 100 μm. n = 6 in each group, * P < 0.05 vs. OE-NC, two-tailed Student’s t-test.

Techniques Used: In Vivo, Injection, Stable Transfection, Transfection, Staining, Two Tailed Test

Schematic illustration of the mechanism whereby CHRDL1 regulates pancreatic cancer. In general, CHRDL1 functions as a BMP antagonist that desensitizes pancreatic cancer cells to BMP-4, thereby inhibiting BMP-mediated SMAD1/5/9 signaling activation. Ultimately, CHRDL1 suppresses malignant behaviors of pancreatic cancer cells and impedes tumor progression in vivo .

Figure Legend Snippet: Schematic illustration of the mechanism whereby CHRDL1 regulates pancreatic cancer. In general, CHRDL1 functions as a BMP antagonist that desensitizes pancreatic cancer cells to BMP-4, thereby inhibiting BMP-mediated SMAD1/5/9 signaling activation. Ultimately, CHRDL1 suppresses malignant behaviors of pancreatic cancer cells and impedes tumor progression in vivo .

Techniques Used: Activation Assay, In Vivo

Over Expression:

Article Title: BMP4 and BMP Antagonists Regulate Human White and Beige Adipogenesis.
Article Snippet: Gene-specific primers and probes were designed using Primer Express software or purchased as Assay-on-Demand (Life Technologies, Stockholm, Sweden). .. Over expression of CHRDL1 7 To overexpress CHRDL1, cells were transfected with a myc-DDK-tagged ORF clone of CHRDL1 obtained from Origene (TrueORF Gold RC202635, BioNordika Sweden) using Lipofectamine 2000 (Life Technologies, Stockholm, Sweden) according to the manufacturers protocol. ..

Transfection:

Image Search Results

Journal: Frontiers in Oncology

Article Title: Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway

doi: 10.3389/fonc.2025.1633464

Figure Lengend Snippet: Decreased expression of CHRDL1 in pancreatic cancer. (A) Data-based prediction of CHRDL1 expression in pancreatic cancer cells, two-tailed Student’s t-test. (B) Association between CHRDL1 and disease-free survival (DFS). (C-E) The efficiency of CHRDL1 overexpression in the pancreatic cancer cell lines PANC-1 and SW1990 was verified using quantitative real-time PCR (RT-qPCR) and Western blot analysis (n = 6, * P < 0.05 vs. hTERT-HPNE, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group). (F, G) IHC analysis of CHRDL1 in tumor and adjacent tissues (n = 6, * P < 0.05 vs. adjacent, two-tailed Student’s t-test).

Article Snippet: The EGFP and CHRDL1 genes (OriGene, #RC202635) were subcloned into the lentiviral vector pLV-EF1a-IRES-Ametrine.

Techniques: Expressing, Two Tailed Test, Over Expression, Real-time Polymerase Chain Reaction, Quantitative RT-PCR, Western Blot

Journal: Frontiers in Oncology

Article Title: Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway

doi: 10.3389/fonc.2025.1633464

Figure Lengend Snippet: Overexpression of CHRDL1 inhibits malignant biological behaviors of PANC-1 and SW1990 cells. (A, B) Representative images of wound healing at 0 and 24 h in CHRDL1 transduced PANC-1 cells, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (C, D) Migration and invasion assays of transfected PANC-1 cells, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). (E, F) Representative images of wound healing at 0 and 24 h in CHRDL1 transduced SW1990 cells, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (G, H) Migration and invasion assays of transfected SW1990 cells, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). n = 6 in each group, * P < 0.05 vs. control, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Article Snippet: The EGFP and CHRDL1 genes (OriGene, #RC202635) were subcloned into the lentiviral vector pLV-EF1a-IRES-Ametrine.

Techniques: Over Expression, Migration, Transfection, Control

Journal: Frontiers in Oncology

Article Title: Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway

doi: 10.3389/fonc.2025.1633464

Figure Lengend Snippet: Overexpression of CHRDL1 inhibits BMP4-Induced SMAD phosphorylation in pancreatic cancer cells. (A, B) p-SMAD 1/5/9, t-SMAD 1/5/9, RUNX2 and CHRDL1 protein levels in PANC-1 cells were detected using Western blots. The immunoblots were calculated by densitometric analysis using GAPDH as the internal reference. (C, D) p-SMAD 1/5/9, t-SMAD 1/5/9, RUNX2 and CHRDL1 protein levels in SW1990 cells were detected using Western blots. The immunoblots were calculated by densitometric analysis using GAPDH as the internal reference. n = 6 in each group, * P < 0.05 vs. OE-NC, # P < 0.05 rhBMP4+OE-NC, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Article Snippet: The EGFP and CHRDL1 genes (OriGene, #RC202635) were subcloned into the lentiviral vector pLV-EF1a-IRES-Ametrine.

Techniques: Over Expression, Phospho-proteomics, Western Blot

Journal: Frontiers in Oncology

Article Title: Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway

doi: 10.3389/fonc.2025.1633464

Figure Lengend Snippet: CHRDL1 attenuates BMP4-induced malignant biological behaviors of pancreatic cancer cells. (A, B) Representative wound healing images of CHRDL1-transduced PANC-1 cells treated with rhBMP4 at 0 and 12 hours, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (C, D) Migration and invasion assays of transfected PANC-1 cells treated with rhBMP4, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm). (E, F) Representative wound healing images of CHRDL1-transduced SW1990 cells treated with rhBMP4 at 0 and 12 hours, along with statistical results of migration distance percentages for each group (Scale bars: 100 μm). (G, H) Migration and invasion assays of transfected SW1990 cells treated with rhBMP4, showing representative images and corresponding statistical analysis for each group (scale bars, upper: 50 μm, lower: 20 μm).n = 6 in each group, *P < 0.05 vs. OE-NC, one-way ANOVA followed by Sidak’s multiple comparisons test for multi-group.

Article Snippet: The EGFP and CHRDL1 genes (OriGene, #RC202635) were subcloned into the lentiviral vector pLV-EF1a-IRES-Ametrine.

Techniques: Migration, Transfection

Journal: Frontiers in Oncology

Article Title: Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway

doi: 10.3389/fonc.2025.1633464

Figure Lengend Snippet: CHRDL1 inhibits pancreatic cancer metastasis in vivo. (A, B) Representative lung images of BALB/c nude mice at 9 weeks after tail vein injection with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). (C, D) Lung weights of BALB/c nude mice at 9 weeks after tail vein injection with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). (E-H) H&E-stained lung sections and corresponding quantitative analysis of tumor area/total lung area from mice injected with OE-NC/OE-CHRDL1 stably transfected PANC-1 cells (left) or SW1990 cells (right). Scale bars, upper: 2 mm, lower: 100 μm. n = 6 in each group, * P < 0.05 vs. OE-NC, two-tailed Student’s t-test.

Article Snippet: The EGFP and CHRDL1 genes (OriGene, #RC202635) were subcloned into the lentiviral vector pLV-EF1a-IRES-Ametrine.

Techniques: In Vivo, Injection, Stable Transfection, Transfection, Staining, Two Tailed Test

Journal: Frontiers in Oncology

Article Title: Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway

doi: 10.3389/fonc.2025.1633464

Figure Lengend Snippet: Schematic illustration of the mechanism whereby CHRDL1 regulates pancreatic cancer. In general, CHRDL1 functions as a BMP antagonist that desensitizes pancreatic cancer cells to BMP-4, thereby inhibiting BMP-mediated SMAD1/5/9 signaling activation. Ultimately, CHRDL1 suppresses malignant behaviors of pancreatic cancer cells and impedes tumor progression in vivo .

Article Snippet: The EGFP and CHRDL1 genes (OriGene, #RC202635) were subcloned into the lentiviral vector pLV-EF1a-IRES-Ametrine.

Techniques: Activation Assay, In Vivo

Expression Levels of CHRDL1 Across Cancers. A Expression levels of CHRDL1 in tumor versus adjacent non-cancerous tissues. B Comparison of CHRDL1 expression levels in tumor and adjacent non-cancerous tissues from the same patient. C Protein expression levels of CHRDL1 in tumor versus adjacent non-cancerous tissues. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)

Journal: BMC Cancer

Article Title: Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma

doi: 10.1186/s12885-025-14174-0

Figure Lengend Snippet: Expression Levels of CHRDL1 Across Cancers. A Expression levels of CHRDL1 in tumor versus adjacent non-cancerous tissues. B Comparison of CHRDL1 expression levels in tumor and adjacent non-cancerous tissues from the same patient. C Protein expression levels of CHRDL1 in tumor versus adjacent non-cancerous tissues. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)

Article Snippet: Details on the cellular localization and immunohistochemical staining of CHRDL1 in both normal and cancerous tissues were retrieved from the Human Protein Atlas database ( https://www.proteinatlas.org/ ).

Techniques: Expressing, Comparison

Journal: BMC Cancer

Article Title: Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma

doi: 10.1186/s12885-025-14174-0

Figure Lengend Snippet: CHRDL1 Expression in Tissues and Its Subcellular Localization. A Subcellular localization profile of CHRDL1 in human cells from the HPA database. B IHC analysis of CHRDL1 expression in LUAD, UCEC, PRAD, COAD, BRCA of IHC. The blue icon for normal tissue and the red icon for tumor tissue

Techniques: Expressing

Association of CHRDL1 expression with the prognosis of various cancers. A Cox proportional hazards model for the correlation of CHRDL1 expression with OS. B Correlation Analysis of CHRDL1 Expression with DSS, PFI, and DFI. C Kaplan–Meier analysis of the association between CHRDL1 expression and overall survival

Journal: BMC Cancer

Article Title: Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma

doi: 10.1186/s12885-025-14174-0

Figure Lengend Snippet: Association of CHRDL1 expression with the prognosis of various cancers. A Cox proportional hazards model for the correlation of CHRDL1 expression with OS. B Correlation Analysis of CHRDL1 Expression with DSS, PFI, and DFI. C Kaplan–Meier analysis of the association between CHRDL1 expression and overall survival

Techniques: Expressing

Mutational characteristics and genetic alterations of CHRDL1 across various tumor types. A Copy number variations of CHRDL1 across different tumors obtained from the cBioPortal database. Blue indicates a deletion, green indicates a structural variant, red represents amplification, and orange denotes a deep deletion. B Mutations of CHRDL1 of Pan-cancer, with a majority being missense mutations. VWC: von Willebrand factor type C domain (31—93); VWC: von Willebrand factor type C domain (109—172); VWC: von Willebrand factor type C domain (254—316). C Genetic alterations of CHRDL1 as reported in The TIMER2.0 database

Journal: BMC Cancer

Article Title: Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma

doi: 10.1186/s12885-025-14174-0

Figure Lengend Snippet: Mutational characteristics and genetic alterations of CHRDL1 across various tumor types. A Copy number variations of CHRDL1 across different tumors obtained from the cBioPortal database. Blue indicates a deletion, green indicates a structural variant, red represents amplification, and orange denotes a deep deletion. B Mutations of CHRDL1 of Pan-cancer, with a majority being missense mutations. VWC: von Willebrand factor type C domain (31—93); VWC: von Willebrand factor type C domain (109—172); VWC: von Willebrand factor type C domain (254—316). C Genetic alterations of CHRDL1 as reported in The TIMER2.0 database

Techniques: Variant Assay, Amplification

Pan-cancer analysis of CHRDL1 expression in relation to immune infiltration and tumor stemness. A Analysis of Immunophenoscore versus CHRDL1 expression levels. B Correlation between CHRDL1 expression and six immune cell types. C Evaluation of CHRDL1 expression and its correlation with ImmuneScore in LUAD, COAD, LUSC, LIHC, and PAAD. D Relationships between CHRDL1 expression and DNAsi and mRNAsi, which reflect the stem-like properties of tumor cells. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)

Journal: BMC Cancer

Article Title: Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma

doi: 10.1186/s12885-025-14174-0

Figure Lengend Snippet: Pan-cancer analysis of CHRDL1 expression in relation to immune infiltration and tumor stemness. A Analysis of Immunophenoscore versus CHRDL1 expression levels. B Correlation between CHRDL1 expression and six immune cell types. C Evaluation of CHRDL1 expression and its correlation with ImmuneScore in LUAD, COAD, LUSC, LIHC, and PAAD. D Relationships between CHRDL1 expression and DNAsi and mRNAsi, which reflect the stem-like properties of tumor cells. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)

Techniques: Expressing

In vitro experiments to validate the effects of CHRDL1 overexpression in A549 and H1299 cell lines. ( A ) qRT-PCR, WB ( B ) Verification of CHRDL1 transfection efficiency of A549 and H1299. The biological effects of CHRDL1 on A549 and H1299 cell lines were verified by CCK- 8 ( C ), Transwell ( D ) and wound healing ( E ) assays. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)

Journal: BMC Cancer

Article Title: Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma

doi: 10.1186/s12885-025-14174-0

Figure Lengend Snippet: In vitro experiments to validate the effects of CHRDL1 overexpression in A549 and H1299 cell lines. ( A ) qRT-PCR, WB ( B ) Verification of CHRDL1 transfection efficiency of A549 and H1299. The biological effects of CHRDL1 on A549 and H1299 cell lines were verified by CCK- 8 ( C ), Transwell ( D ) and wound healing ( E ) assays. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)

Techniques: In Vitro, Over Expression, Quantitative RT-PCR, Transfection, CCK-8 Assay

Experiment of subcutaneous tumors from nude mice ( n = 6) xenografted with CHRDL1-overexpression A549 cells. A & B Comparison of normal A549 cells and subcutaneous transplanted tumors overexpressing CHRDL1 cells. The tumor volume ( C ) and weight ( D ) were quantified. (**, p < 0.01; ***, p < 0.001)

Journal: BMC Cancer

Article Title: Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma

doi: 10.1186/s12885-025-14174-0

Figure Lengend Snippet: Experiment of subcutaneous tumors from nude mice ( n = 6) xenografted with CHRDL1-overexpression A549 cells. A & B Comparison of normal A549 cells and subcutaneous transplanted tumors overexpressing CHRDL1 cells. The tumor volume ( C ) and weight ( D ) were quantified. (**, p < 0.01; ***, p < 0.001)

Techniques: Over Expression, Comparison

Analysis of Chrdl1 mRNA and CHRDL1 protein expression levels in mouse tissues. ( A ) The Chrdl1 L (long-form) and Chrdl1 S (short-form) mRNA expression levels in various mouse tissues. Normalized expression levels in transcripts per million (TPM) values are presented as mean ± SEM. ***, p < 0.001. ( B ) Schematic representation of exon and intron structure of the mouse Chrdl1 gene and the averages of RNA-seq read coverages in BAT, inguinal (iWAT), and epididymal WAT (eWAT) presented in . Arrows denote transcriptional direction. ( C ) The mRNA expression levels of Chrdl1 L , Chrdl1 S , brown-fat-selective gene ( Ucp1 ), and white adipose tissue markers ( Adipoq and Lep ) in iWAT, eWAT, and BAT. TPM values are presented as mean ± SEM. Different letters, a and b, denote statistical difference at a significance level of α = 0.05. ( D ) Western blot analysis of CHRDL1 protein expression in mouse white and brown adipose tissues. The experiment was conducted in duplicate. V+S, recombinant vector carrying CHRDL1 short-form protein (CHRDL1 S); V+L, recombinant vector carrying CHRDL1 long-form protein (CHRDL1 L); EV, empty-vector control; *, non-specific band. The α-tubulin protein was used as a loading control.

Journal: Cells

Article Title: Chordin-like 1, a Novel Adipokine, Markedly Promotes Adipogenesis and Lipid Accumulation

doi: 10.3390/cells12040624

Figure Lengend Snippet: Analysis of Chrdl1 mRNA and CHRDL1 protein expression levels in mouse tissues. ( A ) The Chrdl1 L (long-form) and Chrdl1 S (short-form) mRNA expression levels in various mouse tissues. Normalized expression levels in transcripts per million (TPM) values are presented as mean ± SEM. ***, p < 0.001. ( B ) Schematic representation of exon and intron structure of the mouse Chrdl1 gene and the averages of RNA-seq read coverages in BAT, inguinal (iWAT), and epididymal WAT (eWAT) presented in . Arrows denote transcriptional direction. ( C ) The mRNA expression levels of Chrdl1 L , Chrdl1 S , brown-fat-selective gene ( Ucp1 ), and white adipose tissue markers ( Adipoq and Lep ) in iWAT, eWAT, and BAT. TPM values are presented as mean ± SEM. Different letters, a and b, denote statistical difference at a significance level of α = 0.05. ( D ) Western blot analysis of CHRDL1 protein expression in mouse white and brown adipose tissues. The experiment was conducted in duplicate. V+S, recombinant vector carrying CHRDL1 short-form protein (CHRDL1 S); V+L, recombinant vector carrying CHRDL1 long-form protein (CHRDL1 L); EV, empty-vector control; *, non-specific band. The α-tubulin protein was used as a loading control.

Article Snippet: In addition, for the recombinant CHRDL1 treatment, mouse CHRDL1 recombinant protein (LS-G25628; LSBio) was purchased and treated for the indicated time with the indicated concentrations (0–400 ng/mL).

Techniques: Expressing, RNA Sequencing Assay, Western Blot, Recombinant, Plasmid Preparation

Analysis of CHRDL1 mRNA and CHRDL1 protein expression patterns in human tissues. ( A ) The CHDL1 mRNA expression levels in a variety of human tissues. TPM values are presented as mean ± SEM. ***, p < 0.001. Each data point is displayed in transparent grey dots due to large sample sizes of the GTEx data . The interquartile range shows the middle 50% of values. Whiskers indicate variability outside the upper and lower quartiles. Outliers are shown as data points located outside the whiskers. ( B ) Exon–intron structure of CHRDL1 with the averages of RNA-seq read coverages in BAT, subcutaneous WAT (sWAT), and omental WAT (oWAT) presented in . Transcriptional direction is denoted with an arrow. ( C ) The mRNA expression levels of CHRDL1 , brown-fat-selective genes ( PRDM16 and PGC1α ), and white adipose tissue markers ( ADIPOQ and CFD/ADIPSIN ) in sWAT, oWAT, and BAT. Mean TPMs ± SEM are presented. Different letters, a, b, and c, represent statistical difference at a significance level of α = 0.05. ( D ) Western blot which is representative of two experiments on CHRDL1 protein expression in human tissues. EV, empty-vector control; V+CHRDL1, recombinant vector carrying human CHRDL1 protein; *, non-specific band. The GAPDH protein was used a loading control.

Journal: Cells

Article Title: Chordin-like 1, a Novel Adipokine, Markedly Promotes Adipogenesis and Lipid Accumulation

doi: 10.3390/cells12040624

Figure Lengend Snippet: Analysis of CHRDL1 mRNA and CHRDL1 protein expression patterns in human tissues. ( A ) The CHDL1 mRNA expression levels in a variety of human tissues. TPM values are presented as mean ± SEM. ***, p < 0.001. Each data point is displayed in transparent grey dots due to large sample sizes of the GTEx data . The interquartile range shows the middle 50% of values. Whiskers indicate variability outside the upper and lower quartiles. Outliers are shown as data points located outside the whiskers. ( B ) Exon–intron structure of CHRDL1 with the averages of RNA-seq read coverages in BAT, subcutaneous WAT (sWAT), and omental WAT (oWAT) presented in . Transcriptional direction is denoted with an arrow. ( C ) The mRNA expression levels of CHRDL1 , brown-fat-selective genes ( PRDM16 and PGC1α ), and white adipose tissue markers ( ADIPOQ and CFD/ADIPSIN ) in sWAT, oWAT, and BAT. Mean TPMs ± SEM are presented. Different letters, a, b, and c, represent statistical difference at a significance level of α = 0.05. ( D ) Western blot which is representative of two experiments on CHRDL1 protein expression in human tissues. EV, empty-vector control; V+CHRDL1, recombinant vector carrying human CHRDL1 protein; *, non-specific band. The GAPDH protein was used a loading control.

Techniques: Expressing, RNA Sequencing Assay, Western Blot, Plasmid Preparation, Recombinant

$Fat cell-enriched expression of Chrdl1 , and developmental regulation of Chrdl1 expression in 3T3-L1 cells and mouse white adipose tissue. ( A ) Relative Chrdl1 mRNA expression in stromal vascular (SV) and fat cell (FC) fractions from mouse adipose tissue quantified by real-time PCR. Dlk1 was used a marker for SV enrichment, whereas Fabp4 , Scd1 , and Pparγ were markers for FC enrichment. ( B ) Relative Chrdl1 mRNA expression during adipogenic differentiation of 3T3-L1 preadipocytes [day (d) 0 to 8] quantified by real-time PCR. Fabp4 was used as a marker of adipogenesis. ( C ) Representative western blot of CHRDL1 protein expression during adipogenic differentiation of 3T3-L1 preadipocytes in vitro. The experiment was performed in duplicate. The FABP4 protein was used as a marker for adipogenic differentiation. Coomassie staining and α-tubulin were used as loading controls. V+S, recombinant vector carrying CHRDL1 short-form protein (CHRDL1 S); V+L, recombinant vector carrying CHRDL1 long-form protein (CHRDL1 L); EV, empty-vector control; *, non-specific band. ( D ) Relative Chrdl1 mRNA expression during development of iWAT in vivo (in 2-day to 49-day-old mice) quantified by real-time PCR. Dlk1 was used as a negative marker of adipose development, while Scd1 and Fas were positive markers of adipose development. The Cyc gene was used as a reference gene. Values represent quadruplicate means ± SEM. *, p < 0.05. Different letters, a, b, c and d, indicate statistical difference at a significance level of α = 0.05.$

Journal: Cells

Article Title: Chordin-like 1, a Novel Adipokine, Markedly Promotes Adipogenesis and Lipid Accumulation

doi: 10.3390/cells12040624

Figure Lengend Snippet: Fat cell-enriched expression of Chrdl1 , and developmental regulation of Chrdl1 expression in 3T3-L1 cells and mouse white adipose tissue. ( A ) Relative Chrdl1 mRNA expression in stromal vascular (SV) and fat cell (FC) fractions from mouse adipose tissue quantified by real-time PCR. Dlk1 was used a marker for SV enrichment, whereas Fabp4 , Scd1 , and Pparγ were markers for FC enrichment. ( B ) Relative Chrdl1 mRNA expression during adipogenic differentiation of 3T3-L1 preadipocytes [day (d) 0 to 8] quantified by real-time PCR. Fabp4 was used as a marker of adipogenesis. ( C ) Representative western blot of CHRDL1 protein expression during adipogenic differentiation of 3T3-L1 preadipocytes in vitro. The experiment was performed in duplicate. The FABP4 protein was used as a marker for adipogenic differentiation. Coomassie staining and α-tubulin were used as loading controls. V+S, recombinant vector carrying CHRDL1 short-form protein (CHRDL1 S); V+L, recombinant vector carrying CHRDL1 long-form protein (CHRDL1 L); EV, empty-vector control; *, non-specific band. ( D ) Relative Chrdl1 mRNA expression during development of iWAT in vivo (in 2-day to 49-day-old mice) quantified by real-time PCR. Dlk1 was used as a negative marker of adipose development, while Scd1 and Fas were positive markers of adipose development. The Cyc gene was used as a reference gene. Values represent quadruplicate means ± SEM. *, p < 0.05. Different letters, a, b, c and d, indicate statistical difference at a significance level of α = 0.05.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Marker, Western Blot, In Vitro, Staining, Recombinant, Plasmid Preparation, In Vivo

Effects of overexpression of Chrdl1 in adipogenic differentiation of 3T3-L1 preadipocytes. ( A ) Representative Western blots of HA-tagged CHRDL1 short-form (S-HA) in 293 cell lysates and culture media after transfection. The experiment was performed in triplicate. ( B ) Oil Red O staining and phase-contrast images of S-HA overexpressing 3T3-L1 cells. For quantification, absorbance (ABS) was measured for the ORO-stained lipid droplets at 510 nm. Values are the mean ± SEM of three independent experiments. *, p < 0.05. ( C ) Representative Western blots of overexpressed S-HA protein detected against an anti-HA tag antibody and positive markers of adipogenic differentiation and lipid accumulation (PPARγ and FABP4) in 3T3-L1 cells. The experiment was conducted in duplicate. Cell lysates were collected at day 0, 4, 8, and 12 after induction of adipogenic differentiation. The α-tubulin protein was used as a loading control. EV, empty vector that was transfected as a control. The scale bar indicates 100 µm.

Journal: Cells

Article Title: Chordin-like 1, a Novel Adipokine, Markedly Promotes Adipogenesis and Lipid Accumulation

doi: 10.3390/cells12040624

Figure Lengend Snippet: Effects of overexpression of Chrdl1 in adipogenic differentiation of 3T3-L1 preadipocytes. ( A ) Representative Western blots of HA-tagged CHRDL1 short-form (S-HA) in 293 cell lysates and culture media after transfection. The experiment was performed in triplicate. ( B ) Oil Red O staining and phase-contrast images of S-HA overexpressing 3T3-L1 cells. For quantification, absorbance (ABS) was measured for the ORO-stained lipid droplets at 510 nm. Values are the mean ± SEM of three independent experiments. *, p < 0.05. ( C ) Representative Western blots of overexpressed S-HA protein detected against an anti-HA tag antibody and positive markers of adipogenic differentiation and lipid accumulation (PPARγ and FABP4) in 3T3-L1 cells. The experiment was conducted in duplicate. Cell lysates were collected at day 0, 4, 8, and 12 after induction of adipogenic differentiation. The α-tubulin protein was used as a loading control. EV, empty vector that was transfected as a control. The scale bar indicates 100 µm.

Techniques: Over Expression, Western Blot, Transfection, Staining, Plasmid Preparation

Induced and spontaneous adipogenic differentiation of 3T3-L1 cells with administration of CHRDL1 recombinant protein. ( A ) Schematic timetable of the search for a permissive stage of differentiation by CHRDL1. Adipogenic differentiation without (treatment 1 and 2) or with different periods of CHRDL1 recombinant protein treatment (100 ng/mL) denoted by grey parallel bars (treatment 3 through 8). D0, time of differentiation induction which was preceded or followed by 2-day intervals. −, no induction of differentiation at D0; +, induction of differentiation at D0. ( B ) Oil Red O staining and Western blots of the adipogenic marker FABP4 at day 8 (D8) for each treatment in A. ( C ) Dose-dependent effects of administered CHRDL1 recombinant protein on induced 3T3-L1 adipocyte differentiation and lipid accumulation. The experiment was performed in duplicate. ( D ) Western blots of adipogenic markers with the proteins harvested from C. ( E ) Spontaneous differentiation of 3T3-L1 preadipocytes along with administration of indicated doses of CHRDL1 recombinant protein. The experiment was performed in duplicate. ( F ) Western blot analysis of adipogenic markers for the proteins collected from E. The α-tubulin protein was used as a loading control. Scale bars indicate 100 µm.

Journal: Cells

Article Title: Chordin-like 1, a Novel Adipokine, Markedly Promotes Adipogenesis and Lipid Accumulation

doi: 10.3390/cells12040624

Figure Lengend Snippet: Induced and spontaneous adipogenic differentiation of 3T3-L1 cells with administration of CHRDL1 recombinant protein. ( A ) Schematic timetable of the search for a permissive stage of differentiation by CHRDL1. Adipogenic differentiation without (treatment 1 and 2) or with different periods of CHRDL1 recombinant protein treatment (100 ng/mL) denoted by grey parallel bars (treatment 3 through 8). D0, time of differentiation induction which was preceded or followed by 2-day intervals. −, no induction of differentiation at D0; +, induction of differentiation at D0. ( B ) Oil Red O staining and Western blots of the adipogenic marker FABP4 at day 8 (D8) for each treatment in A. ( C ) Dose-dependent effects of administered CHRDL1 recombinant protein on induced 3T3-L1 adipocyte differentiation and lipid accumulation. The experiment was performed in duplicate. ( D ) Western blots of adipogenic markers with the proteins harvested from C. ( E ) Spontaneous differentiation of 3T3-L1 preadipocytes along with administration of indicated doses of CHRDL1 recombinant protein. The experiment was performed in duplicate. ( F ) Western blot analysis of adipogenic markers for the proteins collected from E. The α-tubulin protein was used as a loading control. Scale bars indicate 100 µm.

Techniques: Recombinant, Staining, Western Blot, Marker

RNA-seq of 3T3-L1 preadipocytes treated with recombinant CHRDL1 protein. ( A ) Volcano plot of differentially expressed genes (DEGs) between treated samples (with recombinant CHRDL1 protein, 100 ng/mL) and untreated controls. Sequencing was performed in triplicates. The x -axis represents log2 transformed fold change. The y -axis represents −log10 transformed adjusted p -value ( P adj), and the larger values indicate more significance. DEGs passed a threshold of |fold change| > 2 and P adj < 0.05 (green dash-dotted lines). Up, up-regulated DEGs in treated samples; Down, down-regulated DEGs in treated samples; NoDEGs, genes that are not differentially expressed. ( B ) Enriched KEGG pathways. The color indicates the q -value, and the lower q -value (darker) indicates the more significant enrichment. The point size indicates DEG numbers. Rich Factor is a value of enrichment factor which is obtained by dividing the number of DEGs by the total number of genes in the corresponding pathway. The larger the Rich Factor, the more the significant enrichment. ( C ) Gene Ontology (GO) enrichment analysis. The x -axis represents the most enriched GO terms in the categories of biological processes, cellular components, and molecular functions. The y -axis represents the number of up- or down-regulated DEGs.

Journal: Cells

Article Title: Chordin-like 1, a Novel Adipokine, Markedly Promotes Adipogenesis and Lipid Accumulation

doi: 10.3390/cells12040624

Figure Lengend Snippet: RNA-seq of 3T3-L1 preadipocytes treated with recombinant CHRDL1 protein. ( A ) Volcano plot of differentially expressed genes (DEGs) between treated samples (with recombinant CHRDL1 protein, 100 ng/mL) and untreated controls. Sequencing was performed in triplicates. The x -axis represents log2 transformed fold change. The y -axis represents −log10 transformed adjusted p -value ( P adj), and the larger values indicate more significance. DEGs passed a threshold of |fold change| > 2 and P adj < 0.05 (green dash-dotted lines). Up, up-regulated DEGs in treated samples; Down, down-regulated DEGs in treated samples; NoDEGs, genes that are not differentially expressed. ( B ) Enriched KEGG pathways. The color indicates the q -value, and the lower q -value (darker) indicates the more significant enrichment. The point size indicates DEG numbers. Rich Factor is a value of enrichment factor which is obtained by dividing the number of DEGs by the total number of genes in the corresponding pathway. The larger the Rich Factor, the more the significant enrichment. ( C ) Gene Ontology (GO) enrichment analysis. The x -axis represents the most enriched GO terms in the categories of biological processes, cellular components, and molecular functions. The y -axis represents the number of up- or down-regulated DEGs.

Techniques: RNA Sequencing Assay, Recombinant, Sequencing, Transformation Assay

The flow chart of the identification of the CHRDL1 function in THCA. CHRDL1 = chordin-like 1, THCA = thyroid cancer.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The flow chart of the identification of the CHRDL1 function in THCA. CHRDL1 = chordin-like 1, THCA = thyroid cancer.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques:

The mRNA expression of CHRDL1 in cancers. (A) The pan-cancer analysis of CHRLD1 in 34 cancers from TCGA and GTEx. (B) The expression of CHRDL1 in THCA and normal tissues was detected according to the independent samples from TCGA database. (C) The expression of CHRDL1 in THCA and normal tissues was detected according to the paired samples from TCGA database. * P < .05, ** P < .01, *** P < .001. CHRDL1 = chordin-like 1. GTEx = genotype-tissue expression, TCGA = the cancer genome atlas, THCA = thyroid cancer.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The mRNA expression of CHRDL1 in cancers. (A) The pan-cancer analysis of CHRLD1 in 34 cancers from TCGA and GTEx. (B) The expression of CHRDL1 in THCA and normal tissues was detected according to the independent samples from TCGA database. (C) The expression of CHRDL1 in THCA and normal tissues was detected according to the paired samples from TCGA database. * P < .05, ** P < .01, *** P < .001. CHRDL1 = chordin-like 1. GTEx = genotype-tissue expression, TCGA = the cancer genome atlas, THCA = thyroid cancer.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

The expression of CHRDL1 in THCA and normal tissues was confirmed based on the GEO datasets including (A) GSE33570, (B) GSE33630, and (C) GSE60542. *** P < .001. CHRDL1 = chordin-like 1, GEO = Gene Expression Omnibus, THCA = thyroid cancer.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The expression of CHRDL1 in THCA and normal tissues was confirmed based on the GEO datasets including (A) GSE33570, (B) GSE33630, and (C) GSE60542. *** P < .001. CHRDL1 = chordin-like 1, GEO = Gene Expression Omnibus, THCA = thyroid cancer.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing, Gene Expression

The protein expression of CHRDL1 in thyroid cells. (A) The normal thyroid glandular cell was obtained from a 76-years-old man. (B) The thyroid glandular cancer cell was obtained from a 75-year-old man. CHRDL1 = chordin-like 1.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The protein expression of CHRDL1 in thyroid cells. (A) The normal thyroid glandular cell was obtained from a 76-years-old man. (B) The thyroid glandular cancer cell was obtained from a 75-year-old man. CHRDL1 = chordin-like 1.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

The comparison of CHRDL1 methylation levels between normal and THCA tissues according to the data from TCGA. The results of CHRDL1 methylation level were presented with a beta value which indicates the level of DNA methylation ranging from 0 (unmethylated) to 1 (fully methylated). CHRDL1 = chordin-like 1, TCGA = the cancer genome atlas, THCA = thyroid cancer.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The comparison of CHRDL1 methylation levels between normal and THCA tissues according to the data from TCGA. The results of CHRDL1 methylation level were presented with a beta value which indicates the level of DNA methylation ranging from 0 (unmethylated) to 1 (fully methylated). CHRDL1 = chordin-like 1, TCGA = the cancer genome atlas, THCA = thyroid cancer.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Comparison, Methylation, DNA Methylation Assay

Box plots determined CHRDL1 expression in different groups of patients based on clinical data from the TCGA datasets. Analysis was shown for (A) gender, (B) age, (C) race, (D) T stages, (E) N stages, (F) M stages, and (G) pathologic stages. * P < .05, ** P < .01, *** P < .001. CHRDL1 = chordin-like 1, TCGA = the cancer genome atlas.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: Box plots determined CHRDL1 expression in different groups of patients based on clinical data from the TCGA datasets. Analysis was shown for (A) gender, (B) age, (C) race, (D) T stages, (E) N stages, (F) M stages, and (G) pathologic stages. * P < .05, ** P < .01, *** P < .001. CHRDL1 = chordin-like 1, TCGA = the cancer genome atlas.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

K–M survival curves compared the high and low expression of CHRDL1 in THCA. Survival curves of (A) OS, (B) DSS, (C) DFI, and (D) PFI time between high and low CHRDL1 expression in patients with THCA. The red lines represented low expression of CHRDL1, while blue lines represented high expression of CHRDL1. CHRDL1 = chordin-like 1, DFI = disease-free interval, DSS = disease-specific survival, K–M = Kaplan–Meier, OS = overall survival, PFI = progression-free interval, THCA = thyroid cancer.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: K–M survival curves compared the high and low expression of CHRDL1 in THCA. Survival curves of (A) OS, (B) DSS, (C) DFI, and (D) PFI time between high and low CHRDL1 expression in patients with THCA. The red lines represented low expression of CHRDL1, while blue lines represented high expression of CHRDL1. CHRDL1 = chordin-like 1, DFI = disease-free interval, DSS = disease-specific survival, K–M = Kaplan–Meier, OS = overall survival, PFI = progression-free interval, THCA = thyroid cancer.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

The univariate and multivariate analyses of age, pathologic stage and CHRDL1 expression in PFI time.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The univariate and multivariate analyses of age, pathologic stage and CHRDL1 expression in PFI time.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

The effect of CHRDL1 expression level on PFI time under different clinical factors. The survival curves showed the effect of high-expressed and low-expressed CHRDL1 on PFI time in the patients (A) < 55 years old, (B) ≥ 55 years old, (C) in pathologic stage I, (D) pathologic stage II, (E) pathologic stage III, or (F) pathologic stage IV. The red lines represented low expression of CHRDL1, while blue lines represented high expression of CHRDL1. CHRDL1 = chordin-like 1, PFI = progression-free interval.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The effect of CHRDL1 expression level on PFI time under different clinical factors. The survival curves showed the effect of high-expressed and low-expressed CHRDL1 on PFI time in the patients (A) < 55 years old, (B) ≥ 55 years old, (C) in pathologic stage I, (D) pathologic stage II, (E) pathologic stage III, or (F) pathologic stage IV. The red lines represented low expression of CHRDL1, while blue lines represented high expression of CHRDL1. CHRDL1 = chordin-like 1, PFI = progression-free interval.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

The correlation between CHRDL1-related genes and PFI time. Survival curves showed the effect of high-expressed and low-expressed (A) SCARA5, (B) CCL21, (C) PODN, (D) DPT, and (E) OSR1 on PFI time. The red lines represented low expression of CHRDL1, while blue lines represented high expression of CHRDL1. CCL21 = C-C motif chemokine ligand 21, CHRDL1 = chordin-like 1, DPT = dermatopontin, OSR1 = odd-skipped related transcription factor 1, PFI = progression-free interval, PODN = podocin, SCARA5 = scavenger receptor class A member 5.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The correlation between CHRDL1-related genes and PFI time. Survival curves showed the effect of high-expressed and low-expressed (A) SCARA5, (B) CCL21, (C) PODN, (D) DPT, and (E) OSR1 on PFI time. The red lines represented low expression of CHRDL1, while blue lines represented high expression of CHRDL1. CCL21 = C-C motif chemokine ligand 21, CHRDL1 = chordin-like 1, DPT = dermatopontin, OSR1 = odd-skipped related transcription factor 1, PFI = progression-free interval, PODN = podocin, SCARA5 = scavenger receptor class A member 5.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

The correlation between PFI time and the expression of CHRDL1 co-expressed genes, including (A) SCARA5, (B) CCL21, (C) PODN, (D) DPT, and (E) OSR1. The red line indicated that these genes and CHRDL1 were co-upregulated. The green line indicated that these genes and CHRDL1 were co-downregulated. CCL21 = C-C motif chemokine ligand 21, CHRDL1 = chordin-like 1, DPT = dermatopontin, OSR1 = odd-skipped related transcription factor 1, PFI = progression-free interval, PODN = podocin, SCARA5 = scavenger receptor class A member 5.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The correlation between PFI time and the expression of CHRDL1 co-expressed genes, including (A) SCARA5, (B) CCL21, (C) PODN, (D) DPT, and (E) OSR1. The red line indicated that these genes and CHRDL1 were co-upregulated. The green line indicated that these genes and CHRDL1 were co-downregulated. CCL21 = C-C motif chemokine ligand 21, CHRDL1 = chordin-like 1, DPT = dermatopontin, OSR1 = odd-skipped related transcription factor 1, PFI = progression-free interval, PODN = podocin, SCARA5 = scavenger receptor class A member 5.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Expressing

The functional pathways of CHRDL1 in THCA. The red line indicated the chemokine signaling pathway; the blue line indicated the T cell receptor signaling pathway; the green line indicated the B cell receptor signaling pathway; the black line indicated the apoptosis; the yellow line indicated the Gonadotropin-releasing hormone (GnRH) receptor signaling pathway. CHRDL1 = chordin-like 1, GnRH = gonadotropin-releasing hormone, THCA = thyroid cancer.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The functional pathways of CHRDL1 in THCA. The red line indicated the chemokine signaling pathway; the blue line indicated the T cell receptor signaling pathway; the green line indicated the B cell receptor signaling pathway; the black line indicated the apoptosis; the yellow line indicated the Gonadotropin-releasing hormone (GnRH) receptor signaling pathway. CHRDL1 = chordin-like 1, GnRH = gonadotropin-releasing hormone, THCA = thyroid cancer.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Functional Assay

GO and KEGG enrichment analysis of CHRDL1 and its co-expressed genes. The GO enrichment analysis was shown for (A) BP, (B) CC, and (C) MF. (D) The main function of CHRDL1 was analyzed by KEGG enrichment analysis. The X-axis was the value of the gene ratio in the term and the Y-axis was the name of the terms. The size of the circles indicated the number of genes enriched in the term, and the color of the circle indicated the P -value. BP = biological processes, CC = cellular component, CHRDL1 = chordin-like 1, GO = Gene Ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: GO and KEGG enrichment analysis of CHRDL1 and its co-expressed genes. The GO enrichment analysis was shown for (A) BP, (B) CC, and (C) MF. (D) The main function of CHRDL1 was analyzed by KEGG enrichment analysis. The X-axis was the value of the gene ratio in the term and the Y-axis was the name of the terms. The size of the circles indicated the number of genes enriched in the term, and the color of the circle indicated the P -value. BP = biological processes, CC = cellular component, CHRDL1 = chordin-like 1, GO = Gene Ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques:

The immune infiltration in cancers. (A) The association between 22 cancers and 39 immune cells was based on the data derived from the TCGA Pan-Cancer dataset. (B) The correlation of CHRDL1 expression and immune infiltration in THCA. * P < .05. CHRDL1 = chordin-like 1, TCGA = the cancer genome atlas, THCA = thyroid cancer.

Journal: Medicine

Article Title: Bioinformatics identify the role of chordin-like 1 in thyroid cancer

doi: 10.1097/MD.0000000000032778

Figure Lengend Snippet: The immune infiltration in cancers. (A) The association between 22 cancers and 39 immune cells was based on the data derived from the TCGA Pan-Cancer dataset. (B) The correlation of CHRDL1 expression and immune infiltration in THCA. * P < .05. CHRDL1 = chordin-like 1, TCGA = the cancer genome atlas, THCA = thyroid cancer.

Article Snippet: Human Protein Atlas was used for exploring the protein expression level of CHRDL1.

Techniques: Derivative Assay, Expressing

Review

chrdl1 genes (OriGene)

Structured Review

Images

1) Product Images from "Chorordin-like 1 inhibits pancreatic cancer cell migration and invasion: involvement of the BMP4/SMAD pathway"

Related Articles

Over Expression:

Transfection:

Similar Products

Image Search Results